TABLE IV.

Characteristics of asthma treatment visits by individual biologic and payer, 2019

Category-specific rates*: rates per 100 biologic-treatment visits in that category	Public insurance (N = 92,759) (27.5%)			Private insurance (N = 244,280) (72.5%)
	OMA	MEP/BENRA	DUP	OMA	MEP/BENRA	DUP
N, treatment visits	33,546	34,835	23,386	89,784	127,200	26,304
Age category (%)
6–14	29.9	0.3	69.8	19.5	79.9	0.6
15–24	29.4	12.3	58.3	61.6	38.2	0.2
25–44	0.1	63.1	36.8	37.3	55.9	6.7
45–64	60.8	4.8	34.5	35.8	47.3	16.9
≥65	38.1	54.0	7.9	23.8	76.1	0.1
Sex (%)
Male	21.6	46.9	31.5	40.0	52.3	7.7
Female	47.2	31.6	21.2	34.5	52.3	13.2
Race and ethnicity (%)
White	41.4	35.1	23.6	29.5	58.6	11.9
Black	0.1	59.8	40.1	37.3	42.5	20.2
Hispanic	0.8	59.4	39.9	30.0	69.9	0.0
Asian/other race	4.8	0.1	0.1	95.9	4.1	0.0
Concomitant medications† (%)
ICS/ICS-LABA use	52.4	28.5	19.1	41.3	52.2	6.5
LTRA	21.2	47.2	31.7	72.3	27.6	0.1
Physician specialty (%)
Allergy/immunology	90.8	9.2	0.0	35.9	43.1	21.0
Pulmonology	13.2	49.5	37.3	29.4	70.6	0.0
Family practice/internal medicine	0.0	59.8	40.2	58.1	25.5	16.4

Actual total number is 335,055 visits (337,039 excluding the 1,984 for reslizumab).

BENRA, Benralizumab; DUP, dupilumab; ICS, inhaled corticosteroid; LABA, long-acting β-agonist; LTRA, leukotriene receptor antagonist; MEP, mepolizumab; OMA, omalizumab.

^*Category-specific rates indicate the rate per 100 visits (%) for that category. For instance, among children aged 6–14 with public insurance, omalizumab accounted for 30% of the “biologic treatment visits.”

^†These categories are not mutually exclusive and do not add up to 100% because some patients were not receiving any of these medications.